These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27511182)

  • 1. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
    Kappos L; Edan G; Freedman MS; Montalbán X; Hartung HP; Hemmer B; Fox EJ; Barkhof F; Schippling S; Schulze A; Pleimes D; Pohl C; Sandbrink R; Suarez G; Wicklein EM;
    Neurology; 2016 Sep; 87(10):978-87. PubMed ID: 27511182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
    Kappos L; Edan G; Freedman MS; Hartung HP; Montalbán X; Barkhof F; Koelbach R; MacManus DG; Wicklein EM;
    J Neurol; 2024 Jul; 271(7):4599-4609. PubMed ID: 38730097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
    Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Bauer L; Dahms S; Lanius V; Pohl C; Sandbrink R;
    Lancet; 2007 Aug; 370(9585):389-97. PubMed ID: 17679016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
    Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
    Edan G; Kappos L; Montalbán X; Polman CH; Freedman MS; Hartung HP; Miller D; Barkhof F; Herrmann J; Lanius V; Stemper B; Pohl C; Sandbrink R; Pleimes D;
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1183-9. PubMed ID: 24218527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
    Kappos L; Polman CH; Freedman MS; Edan G; Hartung HP; Miller DH; Montalban X; Barkhof F; Bauer L; Jakobs P; Pohl C; Sandbrink R
    Neurology; 2006 Oct; 67(7):1242-9. PubMed ID: 16914693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
    Barkhof F; Polman CH; Radue EW; Kappos L; Freedman MS; Edan G; Hartung HP; Miller DH; Montalbán X; Poppe P; de Vos M; Lasri F; Bauer L; Dahms S; Wagner K; Pohl C; Sandbrink R
    Arch Neurol; 2007 Sep; 64(9):1292-8. PubMed ID: 17846268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
    Freedman MS
    Ther Adv Neurol Disord; 2014 Nov; 7(6):279-88. PubMed ID: 25371710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
    Penner IK; Stemper B; Calabrese P; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Pleimes D; Lanius V; Pohl C; Kappos L; Sandbrink R
    Mult Scler; 2012 Oct; 18(10):1466-71. PubMed ID: 22492127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.
    Kinkel RP; Dontchev M; Kollman C; Skaramagas TT; O'Connor PW; Simon JH;
    Arch Neurol; 2012 Feb; 69(2):183-90. PubMed ID: 21987393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.
    Moraal B; Pohl C; Uitdehaag BM; Polman CH; Edan G; Freedman MS; Hartung HP; Kappos L; Miller DH; Montalban X; Lanius V; Sandbrink R; Barkhof F
    Arch Neurol; 2009 Nov; 66(11):1345-52. PubMed ID: 19901165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
    Kinkel RP; Simon JH; O'Connor P; Hyde R; Pace A
    Mult Scler Relat Disord; 2014 Nov; 3(6):712-9. PubMed ID: 25891550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.
    Armoiry X; Kan A; Melendez-Torres GJ; Court R; Sutcliffe P; Auguste P; Madan J; Counsell C; Clarke A
    J Neurol; 2018 May; 265(5):999-1009. PubMed ID: 29356977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.
    Simon JH; Kinkel RP; Kollman C; O'Connor P; Fisher E; You X; Hyde R;
    Mult Scler; 2015 Apr; 21(4):415-22. PubMed ID: 25344370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.